Patient-derived organoids for therapy personalization in inflammatory bowel diseases

doi:10.3748/wjg.v28.i24.2636

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8938)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

471

WORD

HTML

5468

Figures (1-1)

387

Tables (1-3)

423

Sum=6821

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

241

Download

407

Sum=648

Publishing Process of This Article

Item

Count

Browse

473

Download

996

Sum=1469

Jun 28, 2022 (publication date) through Dec 4, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jun 28, 2022; 28(24): 2636-2653
Published online Jun 28, 2022. doi: 10.3748/wjg.v28.i24.2636

Table 3 Potential therapeutic approaches for inflammatory bowel disease treatment identified using intestinal organoids

Potential therapeutic approaches	Effect	Species	Ref.
Sex hormones	Decreased expression of ER stress markers	Human (UC female patients)	[100]
Naltrexone	Reduced ER stress levels, increased the expression of endogenous encephalins and endorphins	Human (IBD patients)	[101]
Bacillus subtilis (RZ001)	Promoted intestinal mucosa repair	Mouse	[102]
Bacterial indoleacrylic acid	Promoted anti-inflammatory cytokines secretion while inducing goblet cells differentiation	Mouse	[103]
Hyaluronan 35 kDa	Promoted epithelial wound healing	Mouse	[106]

ER: Endoplasmic reticulum; IBD: Inflammatory bowel disease; UC: Ulcerative colitis.

Citation: Lucafò M, Muzzo A, Marcuzzi M, Giorio L, Decorti G, Stocco G. Patient-derived organoids for therapy personalization in inflammatory bowel diseases. World J Gastroenterol 2022; 28(24): 2636-2653
URL: https://www.wjgnet.com/1007-9327/full/v28/i24/2636.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i24.2636